Atomoxetine hydrochloride

Research use only, not for human use.

A selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM; shows weak affinity for 5-HT and dopamine transporters with IC50 of 77 and 1,451 nM, respectively.

A selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM; shows weak affinity for 5-HT and dopamine transporters with IC50 of 77 and 1,451 nM, respectively; approved for the treatment of attention deficit hyperactivity disorder (ADHD).Other Indication Approved.

——

Animal Model:Male Sprague-Dawley rats Dosage:0.3, 1 and 3 mg/kg Administration:Intraperitoneal injection; for 4 hours Result:Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold.Animal Model:Spontaneously hypertensive rat (SHR) Dosage:0.1, 0.3, 1.25 and 5.0 mg/kg Administration:Intraperitoneal injection and oral administration; for 14 days Result:Had non-impact on the measurement of motor activity.

Tomoxetine | LY-139603

Membrane Transporter/Ion Channel

Monoamine Transporter

5-HT|DAtransporter|Norepinephrine(NE)transporter

Neurological Disease

Parkinson Disease

82248-59-7

291.8157

C17H22ClNO

>98% (HPLC)

10 mM in DMSO

CC1=CC=CC=C1O[C@@H](C2=CC=CC=C2)CCNC.[H]Cl

Benzenepropanamine, N-methyl-γ-(2-methylphenoxy)-, hydrochloride (1:1), (γR)-

(-20℃)

With Ice Pack

≥ 2 years